Stoneridge Investment Partners LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 12.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 120,853 shares of the company’s stock after selling 17,302 shares during the period. Zoetis makes up approximately 1.1% of Stoneridge Investment Partners LLC’s holdings, making the stock its 24th largest position. Stoneridge Investment Partners LLC’s holdings in Zoetis were worth $7,539,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Baldwin Brothers Inc. MA bought a new position in Zoetis during the first quarter valued at about $2,373,000. Atria Investments LLC boosted its position in Zoetis by 29.3% in the first quarter. Atria Investments LLC now owns 6,399 shares of the company’s stock valued at $342,000 after buying an additional 1,449 shares in the last quarter. Inverness Counsel LLC NY boosted its position in Zoetis by 121.7% in the first quarter. Inverness Counsel LLC NY now owns 370,815 shares of the company’s stock valued at $19,735,000 after buying an additional 203,586 shares in the last quarter. Private Trust Co. NA boosted its position in Zoetis by 6.5% in the first quarter. Private Trust Co. NA now owns 9,010 shares of the company’s stock valued at $480,000 after buying an additional 548 shares in the last quarter. Finally, Jacobs & Co. CA boosted its position in Zoetis by 6.3% in the first quarter. Jacobs & Co. CA now owns 131,709 shares of the company’s stock valued at $7,029,000 after buying an additional 7,837 shares in the last quarter. 92.70% of the stock is currently owned by institutional investors.
Zoetis Inc. (NYSE:ZTS) traded down 0.25% during trading on Friday, hitting $60.75. 1,513,092 shares of the stock traded hands. The company has a market capitalization of $29.71 billion, a P/E ratio of 34.34 and a beta of 1.02. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85. The company’s 50 day moving average is $61.95 and its 200 day moving average is $58.24.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting analysts’ consensus estimates of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same period last year, the business posted $0.49 earnings per share. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Stoneridge Investment Partners LLC Has $7.54 Million Position in Zoetis Inc. (NYSE:ZTS)” was reported by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://rinconhillneighbors.org/2017/08/20/stoneridge-investment-partners-llc-decreases-position-in-zoetis-inc-nysezts-updated.html.
ZTS has been the topic of several recent analyst reports. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Monday, July 17th. Deutsche Bank AG reissued a “buy” rating and set a $65.00 target price (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research note on Tuesday, June 20th. Hilliard Lyons initiated coverage on shares of Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 target price on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and set a $65.00 target price on shares of Zoetis in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. Zoetis presently has a consensus rating of “Buy” and an average price target of $64.78.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.